Voyager Therapeutics stock soars on AbbVie pact worth potentially $1 billion Voyager Therapeutics stock soars on AbbVie pact worth potentially $1 billion
This post was originally published on this site Shares of Voyager Therapeutics Inc. VYGR, +17.78% ran up 14.2% in premarket trade Friday, after the... Voyager Therapeutics stock soars on AbbVie pact worth potentially $1 billion
This post was originally published on this site

Shares of Voyager Therapeutics Inc. VYGR, +17.78% ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. ABBV, +0.24% announced a collaboration to develop antibodies to treat Parkinson’s disease. AbbVie’s stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties. Voyager is also eligible to earn up to a total of $500 million in commercial milestones. Voyager’s stock has lost 10% over the past three months, while AbbVie shares have declined 8.6% and the S&P 500 SPX, +0.41% has gained 4.7%.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *